- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03961373
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer (Neo-D2plus)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective multi-centre phase III, two-group, randomized and controlled trial designed to prove superiority of the experimental treatment arm (neo-adjuvant chemotherapy and super-extended lymphadenectomy).
The trial population consists of patients who have histologically confirmed adenocarcinoma of the stomach with locally advanced primary tumour and no evidence of distant metastases (stage IIA-IIIC gastric cancer). The lymph node clinical metastases, before neo-adjuvant chemotherapy, must be limited to the first and second compartments (stations 1-12).
STANDARD GROUP: Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy.
Patients who are assigned to neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
EXPERIMENTAL GROUP: Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy.
Patients who are assigned to neoadjuvant chemotherapy + surgical D2plus extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2 lymph node dissection plus resection of stations 8p, 12b/p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
In both groups, surgical treatment should be performed within 4-6 weeks after the end of the last cycle of NAC.
The primary objective of this study is to compare overall and cancer-related survival between D2 and D2+ lymphadenectomy following neo-adjuvant chemotherapy for resectable gastric cancer.
In addition, response to chemotherapy, resection rate, quality of life, complications attributable to surgical intervention / side effects of chemotherapy and the duration of hospitalization will be evaluated.
Sample size estimation was performed, to detect the minimum number of patients to be recruited in each arm. A two-sided log rank test with an overall sample size of 539 subjects, of which 270 are in group 1 and 269 are in group 2.
Data will be analyzed using SPSS software. Level of significance will be defined as 5%.
The trial will be open for recruitment from October 2018 to September 2023.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Daniele Marrelli
- Phone Number: +39577585157
- Email: daniele.marrelli@unisi.it
Study Locations
-
-
-
Siena, Italy, 53100
- Recruiting
- General and Surgical Oncology Department, University of Siena
-
Contact:
- Daniele Marrelli
- Phone Number: +39577585157
- Email: daniele.marrelli@unisi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age equal or greater than 18 years
- IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment with NAC. Not including gastro-oesophageal junction/cardia carcinoma but only Siewert 3, without any previous treatment (surgery and / or chemotherapy) for this diagnosis
Lack in CT scan of following:
- Mediastinal lymph nodes
- Lung metastases
- Peritoneal metastases
- Liver metastases
- Pleural effusion, ascites
- Metastases to para-aortic lymph nodes No 16a2/b1
- Metastases to lymph nodes located in the "posterior" area (8p, 12 b/p, 13)
- Extra-regional lymph node metastases
- ECOG performance status ≤ 2
- No prior radio- or chemotherapy conflicting with the treatment of gastric cancer
- No oesophageal invasion, or invasion <=3cm
- Negative peritoneal washing cytology findings and no peritoneal metastases in staging laparoscopy
- No gastric stump cancer
- No signs of cervical and subclavear lymph nodes or distal metastases
- Patient's consent form obtained, signed and dated before beginning specific protocol procedures
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Exclusion Criteria:
- Contraindications for any sort of appropriate chemotherapy according to local standards
- Linitis plastica
- Second uncontrolled malignant tumour (synchronous or metachronous (last 5 years) other than Cis or mucosal cancer
- Neoplasms involving the esophago-gastric junction (Siewert types I and II)
- Expected unresectability after neo-adjuvant treatment or progression in metastases
- Emergency surgery due to bleeding or perforation
- Uncontrolled infections
- Other serious underlying medical conditions that could impair the ability of the patient to participate in the study
- Pregnant or lactating women
- Significant neurologic or psychiatric disorders
- Severe cardiac illness (NYHA class IV)
- Under treatment of systemic steroids
- Participation in any other clinical trial that might interfere with the results of this trial
- Lack of compliance
- Inability to fill in questionnaires (insufficient command of language, dementia, lack of time)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Group
Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
|
Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour.
Standardized D2-lymph node dissection is required with specific information about lymph node stations.
|
Experimental: Experimental Group
Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
|
Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour.
Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival analysis
Time Frame: This outcome measure will be estimated from the time of randomization to the date of death or last follow up visit, assessed approximately 5 years after the disease diagnosis.
|
Overall survival analysis will be analysed during follow up visits
|
This outcome measure will be estimated from the time of randomization to the date of death or last follow up visit, assessed approximately 5 years after the disease diagnosis.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence free-survival
Time Frame: This outcome measure will be estimated from the time of randomization to the date of recurrence, assessed approximately 5 years after the disease diagnosis.
|
That part will also be analysed during follow up visits.
The recurrence has to be documented in radiological, endoscopic or pathological examination, when possible.
|
This outcome measure will be estimated from the time of randomization to the date of recurrence, assessed approximately 5 years after the disease diagnosis.
|
Post-operative morbidity
Time Frame: This outcome measure will be assessed approximately 3 month after the operation date.
|
Severity of post-operative complications will be analysed using Clavien-Dindo classification
|
This outcome measure will be assessed approximately 3 month after the operation date.
|
Post-operative mortality
Time Frame: Within 30 days from operation or during the hospital stay
|
Deaths after surgery
|
Within 30 days from operation or during the hospital stay
|
R0 resection
Time Frame: This outcome measure will be assessed approximately 3 month after the operation date.
|
Absence of microscopic (R1) or macroscopic (R2) residual tumor after surgery
|
This outcome measure will be assessed approximately 3 month after the operation date.
|
Percentage of completion of protocol treatment
Time Frame: This outcome measure will be assessed approximately 12 month after the date of enrollment.
|
Percentage of patients who will complete the protocol treatment, including adjuvant chemotherapy
|
This outcome measure will be assessed approximately 12 month after the date of enrollment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Franco Roviello, University of Siena
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neo-D2plus trial
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Gastric Cancer
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
Huashan HospitalSeattle Integrative Cancer CenterUnknownMetastatic Gastric Cancer | Locally Advanced Gastric CancerChina, United States
-
Gruppo Italiano per lo studio dei Carcinomi dell...Regione LombardiaTerminatedMetastatic Gastric Cancer | Locally Advanced Unresectable Gastric CancerItaly
-
Fudan UniversityUnknownMetastatic Gastric Cancer | Locally Advanced Gastric AdenocarcinomaChina
-
Fujian Medical UniversityNot yet recruitingLocally Advanced Gastric CancerChina
-
Fujian Medical UniversityActive, not recruitingLocally Advanced Gastric CancerChina
-
Fujian Medical UniversityActive, not recruitingLocally Advanced Gastric CancerChina
-
Tianshu LiuCompletedLocally Advanced Gastric CancerChina
Clinical Trials on Gastrectomy with D2 lymphadenectomy
-
Alexandria UniversityCompleted
-
Fujian Medical UniversityThe First Affiliated Hospital of Nanchang University; Chinese PLA General Hospital and other collaboratorsNot yet recruitingGastric Cancer | Robotic GastrectomyChina
-
Southwest Hospital, ChinaCompleted
-
University of Roma La SapienzaAndrea LaghiRecruitingGastric Cancer | Adenocarcinoma of the StomachItaly
-
Fujian Medical UniversityCompleted
-
Yonsei UniversityUnknownGastric CancerKorea, Republic of
-
Fujian Medical UniversityEnrolling by invitation
-
National Cancer Center, KoreaUnknownGastric CancerKorea, Republic of
-
Xijing Hospital of Digestive DiseasesRecruitingPancreatic FistulaChina
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital... and other collaboratorsUnknownGastric Cancer | Surgery | Effects of ChemotherapyChina